Single dose of LSD formulation improves anxiety in Phase 2b trial
The Brown University Psychopharmacology Update November 28, 2025 DOI: 10.1002/pu.31394 via OpenAlex
Summary
AI-generated from the abstractA single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) reduced anxiety in a dose-dependent manner in people with generalized anxiety disorder (GAD), according to a Phase 2b study. The two highest of four tested dose strengths of the MM120 formulation showed significant improvement compared to placebo.
Study at a glance
| Characteristics | Phase 2b clinical trial Peer reviewed |
|---|---|
| Population | Individuals with generalized anxiety disorder (GAD) |
| Topics | Anxiety LSD |
| Keywords | Phase matter Drug Medicine |
| Key finding | The two highest dose strengths of MM120 (LSD formulation) produced significant dose-dependent reductions in anxiety relative to placebo. |
Abstract
Treatment with a single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) resulted in a dose‐dependent reduction in anxiety in individuals with generalized anxiety disorder (GAD), a Phase 2b study has found. The two highest of four tested dose strengths of the MM120 formulation demonstrated significant improvement relative to placebo.